Protocols Back To Search Instructions
9 protocol(s) meet the specified criteria
Disease Site: Esophagus
Protocol No. Title Status
1403GCC An Umbrella Protocol for Collection of Blood, Tumor Tissue, Lymph Node Specimens, normal tissue, effusions CSF fluid and Buccal Samples from Patients with Established or Suspected Solid Tumor Malignancy and Normal Subjects, to be used in Laboratory Research Open
1950GCCC First in Human Phase 1A (dose escalation) and I B (expansion cohorts) Study of [IND # Agent-AG01 a Chimeric Monoclonal Antibody against Glycoprotein GP88] in advanced Solid Tumor Malignancies (1A) with expansion cohorts (1B) in advanced Triple Negative Breast Cancer, Hormone Resistant Breast Cancer, advanced Non-small Cell Lung Cancer (NSCLCA) and advanced Mesothelioma Open
22121GCCC A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment Open
2380GCC A Single Arm phase I-II trial Evaluating Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs based on Residual Circulating Tumor DNA (ctDNA) Levels (SAVAL) Open
2494GCCC Practical clinical interventions to help improve cancer care for patients who live in food priority areas (FPAs) or food deserts. Open
2541GCCC A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-positive Open
2649GCCC A Phase 1/2, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors Open
EA3191 EA3191 A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features Open
EAY191-N5 A Randomized Trial of Neratinib, a Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors Open